尿激酶、重组链激酶和纤溶酶在治疗下肢深静脉血栓中的疗效比较

目的:比较纤溶酶、尿激酶、重组链激酶在治疗下肢深静脉血栓中的临床疗效。方法:选取下肢深静脉血栓病人123例,分为三组,其中尿激酶治疗组50例,重组链激酶治疗组30例,纤溶酶治疗组43例。我们采取相同的治疗方案,每日测量患肢周径,每3d抽血检验凝血四项,D-二聚体,血常规检查。疗程分别为尿激酶5～7d,重组链激酶组4～5d,纤溶酶组约7～10d。结果:尿激酶组与重组链激酶组治疗临床有效率相近,无显著差异(P>0.05),与纤溶酶组比较有显著差异(P<0.05)。结论:三种药物溶栓效果相同,但尿激酶、重组链激酶治疗深静脉血栓优于纤溶酶。

THE CLINICAL EFFECT OF UROKINASE, RECOMBINANT STREPTOKINASE AND FIBRINOGENASE TREATING:LOWER LIMBS OF DEEP VEIN THROMBOSIS

Objective:To compare the clinical effect of using fibrinogenase,urokinase and recombinant streptokinase in the treatment of deep vein thrombosis.Methods:Clinical analysis of 123 cases of pactients with deep vein thrombosis,were divided into urokinawe group(n=50),recombinant streptokinase group(n=30),fibrinogenase group(n=43).We take the same treatment,Daily measurement of limb circumference,Coagulation blood tests,D-dimer,Blood routine examination every three days.Urokinase treatment was 5~7 days,4~5 days of recombinant streptokinase group,group type fibrinogenase about 7-10 days.Results:Recombinant streptokinase,urokinase group and clinical effective similar to the treatment group,no significant difference(P>0.05),compared with fibrinogenase were significantly different(P<0.05).Conclusion:The three drugs can achieve thrombolysis effect,but the effect of urokinase,recombinant streptokinase treatment were excellenter than fibrinogenase group.